Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
McKinsey
Boehringer Ingelheim
Express Scripts
Baxter

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR PERAMPANEL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Perampanel

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00368472 ↗ 4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures Completed Eisai Inc. Phase 2 2006-10-01 The purpose of this study is to determine the safety of perampanel given as adjunctive, long-term treatment in patients with refractory partial onset seizures.
NCT00505284 ↗ An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy Completed Eisai Limited Phase 2/Phase 3 2007-06-01 The purpose of this study is to determine the efficacy and safety of Perampanel in patients with painful diabetic neuropathy.
NCT00505284 ↗ An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy Completed Eisai Inc. Phase 2/Phase 3 2007-06-01 The purpose of this study is to determine the efficacy and safety of Perampanel in patients with painful diabetic neuropathy.
NCT00505622 ↗ Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations Terminated Eisai Limited Phase 3 2007-07-01 This is a multicentre, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of Perampanel (E2007) as an adjunctive therapy in levodopa treated PD subjects with motor fluctuations. All subjects who have completed E2007-E044-213 or E2007-G000-309 will be candidates for entering this extension trial, provided that they meet the inclusion/exclusion criteria and have completed the core study, up to and including the final efficacy visit.
NCT00566462 ↗ Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT Terminated Eisai Inc. Phase 2 2007-10-01 This is a two-arm, double-blind, placebo-controlled study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Perampanel

Condition Name

Condition Name for Perampanel
Intervention Trials
Epilepsy 14
Healthy 4
Refractory Partial Seizures 4
Parkinson's Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Perampanel
Intervention Trials
Seizures 23
Epilepsy 22
Amyotrophic Lateral Sclerosis 4
Epilepsies, Partial 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Perampanel

Trials by Country

Trials by Country for Perampanel
Location Trials
United States 244
Japan 55
Belgium 19
Spain 18
China 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Perampanel
Location Trials
Florida 14
New York 13
Ohio 12
California 12
Texas 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Perampanel

Clinical Trial Phase

Clinical Trial Phase for Perampanel
Clinical Trial Phase Trials
Phase 4 14
Phase 3 12
Phase 2/Phase 3 2
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Perampanel
Clinical Trial Phase Trials
Completed 36
Recruiting 14
Terminated 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Perampanel

Sponsor Name

Sponsor Name for Perampanel
Sponsor Trials
Eisai Inc. 38
Eisai Co., Ltd. 8
Eisai Limited 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Perampanel
Sponsor Trials
Industry 52
Other 30
NIH 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Medtronic
Baxter
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.